SCHEMBL6129189

SCHEMBL6129189

CC(C)(C)NC(=S)NCCc1nc(-c2ccccc2-c2ccccc2)c[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
ALDH1A1 P00352 5/20 0.36
MAPT P10636 4/20 0.36
ALOX12 P18054 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
KDM4E B2RXH2 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1927653 0.89 NPC1 (0.53) NPC1RAB9AALDH1A1MAPTALOX12
SCHEMBL6129186 0.78 CNR2 (0.36) CDK4CCND1EPHX1
SCHEMBL1928222 0.75 NPC1 (0.53) NPC1RAB9AALDH1A1MAPTMEN1
SCHEMBL6129187 0.73 LMNA (0.43) ALDH1A1MEN1KMT2ALMNAMAPK1
SCHEMBL20027158 0.69 RAB9A (1.00) NPC1RAB9AALDH1A1MAPTALOX12
SCHEMBL14736459 0.69 CYP3A4 (0.43) ALDH1A1MAPTMEN1KMT2ALMNA
SCHEMBL14736334 0.69 IDO1 (0.51) ALDH1A1MEN1KMT2ALMNAHTT
SCHEMBL1926706 0.68 ADORA1 (0.46) ALDH1A1LMNAMAPK1HTTSMN1; SMN2
SCHEMBL1928104 0.67 IDO1 (0.49)
SCHEMBL2338147 0.67 LTA4H (0.42) ALDH1A1MAPTMAPK1CYP3A4CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, OPRK1 NPC1 1240/4885RAB9A 3731/4885ALDH1A1 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.